Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Trilostane in Normotensive and Hypertensive Rats

      ,

      Cardiology

      S. Karger AG

      Rats, Trilostane, Treatment

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect of trilostane, a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, on adrenal tissue and blood pressure was studied in normotensive and spontaneously hypertensive rats. The drug was administered orally in doses of 10, 200 and 650 mg/kg/day for 2 and 4 weeks. Trilostane induced an increase in adrenal weight by lipoid transformation of the zona fasciculata. Simultaneously a reduction of retroperitoneal fat tissue was seen in all animals. A significant increase in blood pressure was observed under a trilostane medication of 650 mg/kg/day in normotensive as well as in spontaneously hypertensive rats. Blood pressure under lower doses did not increase significantly. Both increase of blood pressure and reduction of retroperitoneal fat tissue might be caused by increased release and synthesis of catecholamines.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-4079-7
          978-3-318-00139-6
          0008-6312
          1421-9751
          1985
          1985
          11 November 2008
          : 72
          : Suppl 1
          : 122-125
          Affiliations
          Institut für Pathologie (Direktor: Prof. K .-M . Müller ) der Berufsgenossenschaftlichen Krankenanstalten «Bergmannsheil», Universitätsklinik, Bochum, BRD
          Article
          173957 Cardiology 1985;72:122–125
          10.1159/000173957
          3863714
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Paper

          General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology

          Trilostane, Rats, Treatment

          Comments

          Comment on this article